Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siyang Leng

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Journal of Investigative Medicine High Impact Case Reports|July 28, 2017
Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple MyelomaAlisse Hannaford, David Del Bello, Siyang Leng, et al.
BMC Ophthalmology|May 16, 2019
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case seriesBonnie A Sklar, Kalla A Gervasio, Siyang Leng, et al.
Nature Communications|May 28, 2020
Partial cross mapping eliminates indirect causal influencesSiyang Leng, Huanfei Ma, Jürgen Kurths, et al.
Physical Review. E|January 20, 2018
Detection of time delays and directional interactions based on time series from complex dynamical systemsHuanfei Ma, Siyang Leng, Chenyang Tao, et al.
Blood Cancer Journal|February 5, 2020
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myelomaSiyang Leng, Divaya Bhutani, Shahzad Raza, et al.
Leukemia & Lymphoma|February 3, 2018
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitorsSiyang Leng, Suzanne Lentzsch, Yanhan Shen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2012
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanomaAhmad A Tarhini, Siyang Leng, Stergios J Moschos, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
Leukemia & Lymphoma|October 23, 2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaScott F Huntington, Enrico de Nigris, Justin Puckett, et al.
Blood|September 14, 2021
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosisCamille Vanessa Edwards, Nisha Rao, Divaya Bhutani, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Journal of Investigative Medicine High Impact Case Reports|July 28, 2017
Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple MyelomaAlisse Hannaford, David Del Bello, Siyang Leng, et al.
BMC Ophthalmology|May 16, 2019
Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case seriesBonnie A Sklar, Kalla A Gervasio, Siyang Leng, et al.
Nature Communications|May 28, 2020
Partial cross mapping eliminates indirect causal influencesSiyang Leng, Huanfei Ma, Jürgen Kurths, et al.
Physical Review. E|January 20, 2018
Detection of time delays and directional interactions based on time series from complex dynamical systemsHuanfei Ma, Siyang Leng, Chenyang Tao, et al.
Blood Cancer Journal|February 5, 2020
Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myelomaSiyang Leng, Divaya Bhutani, Shahzad Raza, et al.
Leukemia & Lymphoma|February 3, 2018
Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitorsSiyang Leng, Suzanne Lentzsch, Yanhan Shen, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 13, 2012
Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanomaAhmad A Tarhini, Siyang Leng, Stergios J Moschos, et al.
Blood Advances|June 28, 2018
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modelingVernon Wu, Erin Moshier, Siyang Leng, et al.
Leukemia & Lymphoma|October 23, 2023
Ibrutinib discontinuation and associated factors in a real-world national sample of elderly Medicare beneficiaries with chronic lymphocytic leukemiaScott F Huntington, Enrico de Nigris, Justin Puckett, et al.
Blood|September 14, 2021
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosisCamille Vanessa Edwards, Nisha Rao, Divaya Bhutani, et al.
Pageof 4